januari
june
respiratori
sampl
receiv
laboratori
saint
loui
hospit
pari
nasal
aspir
na
bronchoalveolar
lavag
bal
specimen
collect
patient
suspect
upper
lower
respiratori
tract
infect
hospit
special
manag
immunocompromis
patient
respiratori
sampl
collect
diagnosi
acut
respiratori
ill
sampl
immunocompromis
patient
median
age
year
rang
year
given
observ
natur
studi
french
law
requir
ethic
approv
inform
consent
specimen
routin
test
influenza
b
virus
respiratori
syncyti
viru
parainfluenza
virus
immunofluoresc
assay
imagen
dakocytom
trapp
franc
specimen
posit
kipyv
wupyv
test
adenovirus
human
bocaviru
human
rhinovirus
human
metapneumoviru
human
coronavirus
human
pyv
bk
jc
use
pcr
method
total
nucleic
acid
extract
na
bal
stool
specimen
use
easymag
system
marci
l
etoil
franc
kipyv
detect
inhous
realtim
pcr
assay
target
gene
primer
hydrolysi
probe
design
use
primer
express
softwar
appli
biosystem
foster
citi
ca
usa
final
reaction
volum
contain
pmol
pmol
correspond
probe
taqman
univers
master
mix
appli
biosystem
dna
extract
reaction
run
realtim
pcr
system
appli
biosystem
specif
posit
specimen
confirm
use
pcr
nest
pcr
primer
describ
pcr
product
sequenc
compar
previous
describ
sequenc
sweden
australia
genbank
access
no
wupyv
detect
pcr
describ
pcr
product
expect
molecular
weight
sequenc
use
primer
compar
publish
sequenc
genbank
access
no
kipyv
detect
respiratori
sampl
patient
case
confirm
nest
pcr
target
anoth
region
gene
twelv
pcr
product
success
sequenc
share
homolog
publish
sequenc
wupyv
detect
patient
genom
sequenc
show
homolog
report
wupyv
sequenc
six
kipyvposit
patient
coinfect
respiratori
virus
pulmonari
bacteri
infect
appendix
tabl
one
wupyvinfect
patient
exhibit
acut
respiratori
failur
concomit
pneumonia
caus
pseudomona
aeruginosa
infect
none
patient
posit
kipyv
wupyv
test
fungi
respiratori
blood
sampl
posit
aspergillu
spp
clinic
characterist
patient
kipyv
wupyv
infect
gener
outcom
decemb
given
appendix
tabl
wellidentifi
system
immunosuppress
howev
sever
coexist
condit
kipyv
wupyvposit
patient
acut
respiratori
disord
eight
kipyvposit
patient
receiv
allogen
stem
cell
transplant
exhibit
profound
neutropenia
week
respiratori
sampl
found
posit
detect
kipyv
significantli
frequent
among
hematopoiet
stem
cell
transplant
hsct
recipi
among
patient
vs
p
tabl
lung
sinu
imag
assess
comput
tomographi
scan
kipyvposit
patient
lung
parenchyma
abnorm
note
patient
sinus
diagnos
patient
take
consider
frequenc
digest
symptom
patient
former
publish
detect
kipyv
stool
sampl
look
kipyv
infect
avail
stool
sampl
respiratori
sampl
assess
kipyv
strikingli
sampl
test
posit
kipyv
cycl
threshold
valu
collect
hsct
recipi
addit
hsct
patient
experienc
diarrhea
demonstr
persist
excret
kipyv
consecut
stool
specimen
collect
june
end
novemb
data
shown
studi
show
preval
kipyv
wupyv
among
immunocompromis
patient
respiratori
disord
previous
virus
observ
mainli
young
children
adult
patient
kipyv
wupyv
infect
mention
studi
immunocompromis
consid
seemingli
higher
preval
kipyv
popul
immunocompromis
patient
may
suscept
pyv
jc
bk
virus
result
previou
report
suggest
similar
frequenc
kipyv
wupyv
infect
found
respiratori
specimen
rang
contrast
seri
found
like
differ
preval
kipyv
wupyv
suggest
replic
reactiv
virus
respiratori
tract
may
differ
immunocompromis
immunocompet
patient
howev
differ
requir
investig
particular
use
similar
realtim
pcr
assay
notabl
significantli
higher
preval
kipyv
infect
found
among
hsct
patient
suggest
profound
tcell
defici
may
factor
facilit
kipyv
replic
report
popul
patient
yield
posit
specimen
kipyv
wupyv
condit
rang
common
cold
acut
respiratori
distress
requir
invas
ventil
respiratori
coinfect
observ
studi
like
account
least
clinic
featur
patient
kipyv
sole
pathogen
detect
respiratori
tract
despit
comprehens
screen
virus
bacteria
parasit
fungi
clinic
radiograph
pattern
vari
patient
upper
respiratori
tract
infect
notabl
sinus
wherea
other
lung
parenchyma
abnorm
defin
comput
tomograph
scan
imag
howev
due
retrospect
natur
studi
therefor
lack
control
group
immunocompromis
patient
without
respiratori
symptom
associ
kipyv
infect
occurr
respiratori
diseas
state
definit
conclus
seemingli
higher
frequenc
kipyv
shed
immunocompromis
patient
observ
pyv
detect
kipyv
singl
pathogen
respiratori
diseas
eg
cytomegaloviru
recurr
lead
pneumonia
immunocompromis
patient
togeth
support
reactiv
hypothesi
nevertheless
reinfect
hypothesi
exclud
due
immunocompromis
patient
increas
risk
acquir
viral
infect
exogen
sourc
control
prospect
studi
kipyv
shed
immunosuppress
help
determin
pathogen
role
viru
clinic
implic
kipyv
detect
stool
mechan
underli
concomit
presenc
gastrointestin
respiratori
tract
also
deserv
analysi
